Peking University People's Hospital: Leukemia, Myeloid, Acute trials

The registry lists 16 Leukemia, Myeloid, Acute studies with Peking University People's Hospital as lead sponsor. 13 are open to participants now and 0 have results posted.

Early Phase 1 1Phase 1 2Phase 2 5Phase 3 3No phase 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• NAC for Hematopoietic Recovery in Low/Intermediate-Risk AML After CR: A Randomized Controlled StudyNot yet recruitingNCT07869342Not applicable
• Leukemia Stem Cell-based Assay to Predict Relapse and Survival in Patients With Acute Myeloid LeukemiaRecruitingNCT07537738
• Digital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AMLRecruitingNCT07500441
• IFN-α in Relapse Prevention.Not yet recruitingNCT07449286Phase 2
• Shortened Venetoclax Duration Based on Day 14 BM Blasts Versus Standard Therapy in Elderly or Frail Patients With AML Patients Treated With Azacitidine Plus VenetoclaxNot yet recruitingNCT07407660Phase 3
• Pre-DLI or Pro-DLI in Relapsed/Refractory Myeloid Neoplasms After HSCTNot yet recruitingNCT07319793Not applicable
• Thiotepa Combined With Busulfan and Fludarabine Conditioning Regimen for Haploidentical Hematopoietic Stem Cell Transplantation in Elderly Patients With High-Risk Acute Myeloid LeukemiaRecruitingNCT06869265Phase 2
• Interferon-alpha As Maintenance Therapy for Favorable-risk Acute Myeloid LeukemiaRecruitingNCT06802718Phase 3
• Using Multiparametric Flow Cytometry to Detect Peripheral Blood and Bone Marrow Leukaemia Stem Cells for Relapse Prediction in P-AMLRecruitingNCT06452732
• MRD Response-adapted Allo-HSCT for Adverse-risk AMLRecruitingNCT06301425Not applicable
• Off-the-shelf CD123 CAR-NK for R/R AMLRecruitingNCT06201247Early Phase 1
• Clinical Study of Venetoclax Combined With CAG in the Treatment of Refractory/Relapsed Acute Myeloid LeukemiaRecruitingNCT05918198Phase 2
• Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCTRecruitingNCT03793517Phase 2/3
• NAC for Promoting Hematopoietic Recovery in Patients With Acute Myeloid Leukemia After ChemotherapyActive, not recruitingNCT06024031Phase 2
• LILRB4 STAR-T Cells in the Treatment of R/R AML/CMMLCompletedNCT05548088Phase 1
• NK Cell Infusion for Patients With Acute Myeloid LeukemiaStatus unknownNCT04221971Phase 1